ArticleAmerican journal of men's health
Variation in Clinically Significant Prostate Cancer on Fusion Biopsy of PI-RADS 3-5 Lesions Based on Ethnicity.
Article in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our aim is to investigate the prevalence of clinically significant prostate cancer (Gleason score 3+4 or higher) on fusion biopsy for Prostate Imaging Reporting and Data System (PI-RADS) 3-5 lesions based on ethnicity. A retrospective analysis was conducted on patients who underwent fusion biopsy between 2016 and 2022 at two institutions. The prevalence of Gleason score 3+4 or higher within each ethnic group (Caucasian, African American, and Hispanics) was assessed. Possible correlation between PI-RADS lesion score and race was also assessed. Among the 918 patients included in the analysis, 54% were Caucasian, 29% were African American, and 17% were Hispanic. A total of 1,384 lesions were identified (PI-RADS 3-34%, PI-RADS 4-40%, and PI-RADS 5-26%). The prevalence of clinically significant prostate cancer by PI-RADS score and ethnicity was similar: (PI-RADS 3-Caucasian 13%, African American 13%, and Hispanic 9%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.